Chitasombat Maria Nina, Watcharananan Siriom P
J Med Assoc Thai. 2016 Apr;99(4):381-5.
Varicella zoster (VZV) is a potentially life-threatening infection after kidney transplantation (KT) but data on the incidence and outcome of late KT VZV infection is limited.
A retrospective study of disseminated VZV infection (D-VZV) in post KT patients was conducted between 2003 and 2013. Acyclovir prophylaxis was given routinely for six months after KT Statistical analyses were performed by SPSS software version 17.0.
Prevalence of D-VZV was 2% [22/1,032 patients]. Patients median age were 40 (21-67) years old and 12 (55%) were male. Timing of the infection was mostly (68.2%) late (> 1 year) post KT The majority of maintenance immunosuppressive drug included prednisolone (95.5%), cyclosporine (77.3%), mycophenolate (68.2%). Two (9.1%) had a recent VZV exposure and four (18%) received intensified immunosuppression before the diagnosis. Common clinical presentations were lymphopenia (54.5%), generalized vesicular rash (50%), and multi-dermatomal distribution (50%) while liver involvement was infrequent (9.1%). None had pneumonitis or neurological involvement. All cases received systemic acyclovir with the median duration of 14 (3-31) days. One had received IVIG for fulminant hepatitis. Immunosuppressive drug/s was reduced in 59%. Median duration of hospitalization was seven (3-37) days. None of patients died. The median follow-up duration was 1939 (IQR 804-2440) days. Recurrent infection was uncommon (4.5%). Secondary prophylaxis was given only in one patient with fulminant VZV hepatitis.
Incidence of D-VZV post KT was low. Treatments with intravenous acyclovir and reduction of immunosuppression without the use of VZV IgG provided favorable outcome in resource-limited settings.
水痘带状疱疹病毒(VZV)感染在肾移植(KT)后可能危及生命,但关于晚期KT患者VZV感染的发病率和转归的数据有限。
对2003年至2013年间KT术后播散性VZV感染(D-VZV)患者进行回顾性研究。KT术后常规给予阿昔洛韦预防6个月。采用SPSS 17.0软件进行统计分析。
D-VZV的患病率为2%[22/1032例患者]。患者中位年龄为40(21-67)岁,12例(55%)为男性。感染时间大多(68.2%)为KT术后晚期(>1年)。大多数维持性免疫抑制药物包括泼尼松龙(95.5%)、环孢素(77.3%)、霉酚酸酯(68.2%)。2例(9.1%)近期有VZV暴露史,4例(占18%)在诊断前接受了强化免疫抑制治疗。常见临床表现为淋巴细胞减少(54.